0241.HK Alibaba Health HKSE close +10.23% at HK$6.36 13 Jan 2026: heavy volume
We saw strong activity in 0241.HK stock as Alibaba Health Information Technology Limited (0241.HK) closed at HK$6.36 on the Hong Kong Stock Exchange (HKSE) on 13 Jan 2026, up 10.23% from the prior close. Volume surged to 358,584,446.00 shares versus an average of 73,693,999.00, driving a large intraday range from HK$5.80 to HK$6.42. In Hong Kong (HKD), this move pushed market cap near HK$102,397,740,185.00 and highlighted the stock as one of the most active names on the HKSE today. We track drivers below and what this means for investors
0241.HK stock: Today’s price action and volume drivers
Alibaba Health (0241.HK) rallied to HK$6.36, a +10.23% gain on the day with a high of HK$6.42 and low of HK$5.80. Trade size hit 358,584,446.00 shares, almost 4.86 times average volume, signalling heavy institutional or block activity.
The move came without a single large public headline, suggesting order flow, sector rotation into healthcare names, and short-covering were major contributors to the intraday surge.
0241.HK stock: Fundamentals and valuation snapshot
On fundamentals, Alibaba Health shows EPS HK$0.13 and a trailing PE at 48.92 based on the latest full quote. Price averages stand at HK$5.51 (50-day) and HK$5.31 (200-day), indicating recent positive momentum.
Key ratios: price/sales 2.20, price/book 4.77, current ratio 2.71, and net profit margin 5.83%. These metrics show solid cash conversion but a premium valuation versus some healthcare peers in Hong Kong.
0241.HK stock: Technicals and short-term setup
Momentum readings favour buyers: RSI 63.65, ADX 30.52 (strong trend), CCI 193.05 (overbought). Bollinger middle sits at HK$5.29 and ATR at HK$0.17, so volatility is elevated.
Technicals suggest a near-term pullback risk after a sharp advance, but trend indicators show strength that may attract momentum traders on HKSE.
0241.HK stock: Sector context and peers
Alibaba Health operates in Healthcare within the Hong Kong market where the sector YTD performance is 6.16% and 1Y 68.50%, reflecting strong interest in health-tech and online pharmacy plays. Investors are comparing 0241.HK against names like JD Health (6618.HK) and WuXi AppTec (2359.HK).
Sector metrics show average PE near 31.46, so 0241.HK’s current PE of 48.92 positions it as relatively expensive versus peers on earnings multiple.
0241.HK stock: Meyka Stock Grade and analyst context
Meyka AI rates 0241.HK with a score out of 100. Meyka AI rates 0241.HK with a score of 68.88 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Company rating snapshots show mixed signals: ROA/ROE and cash metrics are strong, while PE-based valuation scores suggest caution. These grades are informational only and are not financial advice.
0241.HK stock: Forecasts and price targets
Meyka AI’s forecast model projects yearly HK$7.22, quarterly HK$6.63, and monthly HK$5.54 for 0241.HK stock. Compared with the current HK$6.36, the one-year projection implies an upside of 13.47%.
Forecasts are model-based projections and not guarantees. We present this to show where algorithmic consensus and fundamentals align today.
Final Thoughts
0241.HK stock closed strongly at HK$6.36 on 13 Jan 2026, up 10.23% on heavy volume of 358,584,446.00 shares, marking it among the HKSE’s most active issues. The rally reflects heavy order flow and positive sector momentum, but valuation remains rich with a trailing PE of 48.92 and price/book 4.77. Meyka AI rates 0241.HK at 68.88/100 (Grade B, HOLD) after weighing peer performance, financial growth and cash metrics. Meyka AI’s forecast model projects a one-year price of HK$7.22, an implied upside of 13.47% versus today’s price HK$6.36. That projection sits alongside clear short-term overbought technicals, so our view is cautious: active traders may prefer momentum plays while longer-term investors should watch earnings, margin trends, and regulatory news in China’s healthcare e-commerce space. Forecasts are model outputs and not guarantees; always align positions with risk tolerance and time horizon. Sources: Reuters company profile and Investing.com summary. Meyka AI provided this analysis as an AI-powered market analysis platform.
FAQs
What drove the 0241.HK stock rally on 13 Jan 2026?
The rally was driven by heavy volume of 358,584,446.00 shares, likely large orders and short-covering. Sector rotation into healthcare names and positive market momentum on the HKSE also supported 0241.HK stock
How is 0241.HK stock valued versus peers?
0241.HK trades at a trailing PE of 48.92 and price/book 4.77, above the healthcare sector average PE of 31.46, indicating a premium valuation for Alibaba Health on key multiples
What is Meyka AI’s outlook for 0241.HK stock?
Meyka AI’s forecast model projects HK$7.22 in one year for 0241.HK stock, implying about 13.47% upside from HK$6.36. Forecasts are model-based projections and not guarantees
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
